Get the Stockscreener App
23.56
2.88%
0.66
Acadia Pharmaceuticals Inc stock is traded at $23.56, with a volume of 1.35M.
It is up +2.88% in the last 24 hours and up +10.77% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$22.90
Open:
$23.04
24h Volume:
1.35M
Relative Volume:
0.67
Market Cap:
$3.99B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
130.89
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
-1.92%
1M Performance:
+10.77%
6M Performance:
+7.83%
1Y Performance:
+45.61%
1-Day Range:
$22.84
$23.98
1-Week Range:
$22.81
$24.50
52-Week Range:
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.56 | 3.87B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
How ACADIA Pharmaceuticals Inc. stock trades before earningsInsider Buying & Real-Time Market Trend Scan - newser.com
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - BioSpace
Is ACADIA Pharmaceuticals Inc. stock oversold or undervalued2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Parkinson's Disease Psychosis Market Size (7MM) was ~USD 665 - openPR.com
Will ACADIA Pharmaceuticals Inc. stock split again soonShare Buyback & Verified Entry Point Detection - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathPortfolio Risk Report & Free Technical Pattern Based Buy Signals - newser.com
Will ACADIA Pharmaceuticals Inc. stock attract more institutional investorsPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
ACADIA Pharmaceuticals (ACAD): JP Morgan Lowers Price Target to $31.00 | ACAD Stock News - GuruFocus
Acadia Eyes Record-Breaking Revenue In 2025 With Nuplazid And Daybue - RTTNews
Is ACADIA Pharmaceuticals Inc. stock trading near support levels2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementWeekly Investment Recap & Verified Stock Trade Ideas - newser.com
ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights - MSN
(ACAD) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings - simplywall.st
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - Yahoo Finance
Why Acadia Pharmaceuticals (ACAD) is a Top Momentum Stock for the Long-Term - sharewise.com
Director Cashes Out: Major Stock Sale at ACADIA Pharmaceuticals! - TipRanks
Acadia Pharmaceuticals director Daly sells $670k in stock By Investing.com - Investing.com Australia
Insider Sell: James Daly Sells 30,000 Shares of ACADIA Pharmaceu - GuruFocus
Acadia Pharmaceuticals director Daly sells $670k in stock - Investing.com
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersEarnings Summary Report & Daily Stock Momentum Reports - newser.com
Acadia Pharmaceuticals stock price target lowered by RBC on weak Medicaid volume - Investing.com Australia
What drives ACADIA Pharmaceuticals Inc stock priceVolatility Trading Techniques & Free Explosive Earning Power - earlytimes.in
Positive readouts validate pipelines, fuel drug developer rally - BioWorld MedTech
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):